OnKure Therapeutics annual r&d spending
2020
2021
2022
2023
2024
2025
OnKure Therapeutics R&D Spending Growth & History (OKUR)
OnKure Therapeutics's r&d spending was $48.3M for fiscal 2025.
View full OnKure Therapeutics company overviewOnKure Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $48.3M | $4.5M | +10.20% |
| 2024 | 2024-12-31 | $43.8M | $11.7M | +36.37% |
| 2023 | 2023-12-31 | $32.1M | −$5.6M | −14.83% |
| 2022 | 2022-12-31 | $37.7M | $9.5M | +33.85% |
| 2021 | 2021-12-31 | $28.2M | $12.2M | +76.67% |
| 2020 | 2020-12-31 | $15.9M | — | — |
OnKure Therapeutics quarterly r&d spending
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $12.6M | −$2,000 | −0.02% |
| Q1 2026 | 2026-03-31 | $11.7M | −$1.3M | −10.03% |
| Q4 2025 | 2025-12-31 | $10.7M | −$3.6M | −25.35% |
| Q3 2025 | 2025-09-30 | $11.9M | $1.8M | +17.78% |
| Q2 2025 | 2025-06-30 | $12.6M | $1.9M | +17.31% |
| Q1 2025 | 2025-03-31 | $13.0M | $4.4M | +51.90% |
| Q4 2024 | 2024-12-31 | $14.4M | — | — |
| Q3 2024 | 2024-09-30 | $10.1M | −$3.5M | −25.74% |
| Q2 2024 | 2024-06-30 | $10.8M | −$3.6M | −25.33% |
| Q1 2024 | 2024-03-31 | $8.6M | −$2.4M | −22.06% |
| Q3 2023 | 2023-09-30 | $13.6M | $3.7M | +37.07% |
| Q2 2023 | 2023-06-30 | $14.4M | $6.3M | +77.08% |
| Q1 2023 | 2023-03-31 | $11.0M | $1.7M | +18.46% |
| Q4 2022 | 2022-12-31 | $10.4M | $3.3M | +45.87% |
| Q3 2022 | 2022-09-30 | $9.9M | $620,000 | +6.65% |
| Q2 2022 | 2022-06-30 | $8.1M | $1.9M | +29.51% |
| Q1 2022 | 2022-03-31 | $9.3M | $3.8M | +69.55% |
| Q4 2021 | 2021-12-31 | $7.1M | $2.0M | +38.73% |
| Q3 2021 | 2021-09-30 | $9.3M | $4.9M | +110.29% |
| Q2 2021 | 2021-06-30 | $6.3M | $3.5M | +122.90% |
| Q1 2021 | 2021-03-31 | $5.5M | $1.9M | +52.93% |
| Q4 2020 | 2020-12-31 | $5.1M | — | — |
| Q3 2020 | 2020-09-30 | $4.4M | — | — |
| Q2 2020 | 2020-06-30 | $2.8M | — | — |
| Q1 2020 | 2020-03-31 | $3.6M | — | — |
OnKure Therapeutics r&d spending trends
Over the last five fiscal years, OnKure Therapeutics's r&d spending increased from $15.9M to $48.3M, a change of $32.3M. The latest reported quarter, Q2 2026, shows $12.6M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review OnKure Therapeutics source filings ↗